Kaley, Thomas

Publications

Sort by

Co-Author Network

selected publications

Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma. Blood. 2018 Academic Article GET IT
Times cited: 123
Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma. Neuro-oncology. 2017 Academic Article GET IT
Times cited: 21
Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma. Cancer discovery. 2017 Academic Article GET IT
Times cited: 243
Phase I study of RO4929097 with bevacizumab in patients with recurrent malignant glioma. Journal of neuro-oncology. 2016 Academic Article GET IT
Times cited: 36
Molecular and Clinical Effects of Notch Inhibition in Glioma Patients: A Phase 0/I Trial. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 Academic Article GET IT
Times cited: 78
Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma. Neuro-oncology. 2015 Academic Article GET IT
Times cited: 139
Large-volume low apparent diffusion coefficient lesions predict poor survival in bevacizumab-treated glioblastoma patients. Neuro-oncology. 2015 Academic Article GET IT
Times cited: 25
Central Nervous System Cancers, Version 1.2015. Journal of the National Comprehensive Cancer Network : JNCCN. 2015 Academic Article GET IT
Times cited: 81
Dynamic contrast enhanced T1 MRI perfusion differentiates pseudoprogression from recurrent glioblastoma. Journal of neuro-oncology. 2015 Academic Article GET IT
Times cited: 89
A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma. Neuro-oncology. 2015 Academic Article GET IT
Times cited: 41
A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Academic Article GET IT
Times cited: 61
Benign brain tumors and tumors associated with phakomatoses. Continuum (Minneapolis, Minn.). 2015 Review GET IT
Times cited: 5
R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood. 2015 Academic Article GET IT
Times cited: 225
Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review. Journal of neurosurgery. 2015 Review GET IT
Times cited: 389
Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. Neurology. 2014 Academic Article GET IT
Times cited: 80
Whole-brain radiotherapy in patients with brain metastases from melanoma. CNS oncology. 2014 Academic Article GET IT
Times cited: 14
Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Academic Article GET IT
Times cited: 78
Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. Neuro-oncology. 2014 Academic Article GET IT
Times cited: 182
Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review. Neuro-oncology. 2014 Review GET IT
Times cited: 164
Bevacizumab for acute neurologic deterioration in patients with glioblastoma. CNS oncology. 2013 Academic Article GET IT
Times cited: 6
Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma. Neuro-oncology. 2012 Academic Article GET IT
Times cited: 87
Dropped head syndrome: report of three cases during treatment with a MEK inhibitor. 2012 GET IT
Times cited: 23
Temozolomide or bevacizumab for spinal cord high-grade gliomas. Journal of neuro-oncology. 2012 Academic Article GET IT
Times cited: 40
Atypical and anaplastic meningiomas treated with bevacizumab. Journal of neuro-oncology. 2012 Academic Article GET IT
Times cited: 133
Therapy of chemotherapy-induced peripheral neuropathy. British journal of haematology. 2009 Review GET IT
Times cited: 136
Postictal laughter following absence status epilepticus. 2003 GET IT
Times cited: 3

more ...

less ...

Background

education and training

M.D., New York University School of Medicine 2003
B.S., Fordham University 1999

Contact

full name

Thomas Kaley

VIVO Weill Cornell Medical College

Thomas Kaley Assistant Professor of Neurology

Publications

selected publications

Background

education and training

Contact

full name